ZYME Quote, Financials, Valuation and Earnings

Arvinas has a net margin of -75.75% compared to Zymeworks's net margin of -76.18%. Zymeworks's return on equity of -30.45% beat Arvinas's return on equity of -32.96%.

Zymeworks has a consensus price target of $21.35, signalling upside risk potential of 115.44%. On the other hand Arvinas has an analysts' consensus of $39.47 which suggests that it could grow by 537.7%. Given that Arvinas has higher upside potential than Zymeworks, analysts believe Arvinas is more attractive than Zymeworks.

Zymeworks has a beta of 1.176, which suggesting that the stock is 17.59% more volatile than S&P 500. In comparison Arvinas has a beta of 2.305, suggesting its more volatile than the S&P 500 by 130.541%.

Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks pays -- of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

Zymeworks quarterly revenues are $31M, which are smaller than Arvinas quarterly revenues of $59.2M. Zymeworks's net income of -$23.5M is higher than Arvinas's net income of -$45.1M. Notably, Zymeworks's price-to-earnings ratio is -- while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 9.85x versus 1.69x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -75.75% compared to Zymeworks's net margin of --. Zymeworks's return on equity of -30.45% beat Perspective Therapeutics's return on equity of --.

Zymeworks has a consensus price target of $21.35, signalling upside risk potential of 115.44%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 741.69%. Given that Perspective Therapeutics has higher upside potential than Zymeworks, analysts believe Perspective Therapeutics is more attractive than Zymeworks.

Zymeworks has a beta of 1.176, which suggesting that the stock is 17.59% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Zymeworks quarterly revenues are $31M, which are larger than Perspective Therapeutics quarterly revenues of --. Zymeworks's net income of -$23.5M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Zymeworks's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 9.85x versus 11.07x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Rocket Pharmaceuticals has a net margin of -75.75% compared to Zymeworks's net margin of --. Zymeworks's return on equity of -30.45% beat Rocket Pharmaceuticals's return on equity of --.

Zymeworks has a consensus price target of $21.35, signalling upside risk potential of 115.44%. On the other hand Rocket Pharmaceuticals has an analysts' consensus of $41.60 which suggests that it could grow by 768.48%. Given that Rocket Pharmaceuticals has higher upside potential than Zymeworks, analysts believe Rocket Pharmaceuticals is more attractive than Zymeworks.

Zymeworks has a beta of 1.176, which suggesting that the stock is 17.59% more volatile than S&P 500. In comparison Rocket Pharmaceuticals has a beta of 1.000, suggesting its less volatile than the S&P 500 by 0.0029999999999974%.

Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rocket Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks pays -- of its earnings as a dividend. Rocket Pharmaceuticals pays out -- of its earnings as a dividend.

Zymeworks quarterly revenues are $31M, which are larger than Rocket Pharmaceuticals quarterly revenues of --. Zymeworks's net income of -$23.5M is higher than Rocket Pharmaceuticals's net income of -$60.3M. Notably, Zymeworks's price-to-earnings ratio is -- while Rocket Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 9.85x versus -- for Rocket Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Stoke Therapeutics has a net margin of -75.75% compared to Zymeworks's net margin of -46.35%. Zymeworks's return on equity of -30.45% beat Stoke Therapeutics's return on equity of -44.32%.

Zymeworks has a consensus price target of $21.35, signalling upside risk potential of 115.44%. On the other hand Stoke Therapeutics has an analysts' consensus of $23.88 which suggests that it could grow by 304.66%. Given that Stoke Therapeutics has higher upside potential than Zymeworks, analysts believe Stoke Therapeutics is more attractive than Zymeworks.

Zymeworks has a beta of 1.176, which suggesting that the stock is 17.59% more volatile than S&P 500. In comparison Stoke Therapeutics has a beta of 1.089, suggesting its more volatile than the S&P 500 by 8.901%.

Zymeworks has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zymeworks pays -- of its earnings as a dividend. Stoke Therapeutics pays out -- of its earnings as a dividend.

Zymeworks quarterly revenues are $31M, which are larger than Stoke Therapeutics quarterly revenues of $22.6M. Zymeworks's net income of -$23.5M is lower than Stoke Therapeutics's net income of -$10.5M. Notably, Zymeworks's price-to-earnings ratio is -- while Stoke Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zymeworks is 9.85x versus 8.69x for Stoke Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.